AU2020323925A1 - Antibodies to Candida and uses thereof - Google Patents

Antibodies to Candida and uses thereof Download PDF

Info

Publication number
AU2020323925A1
AU2020323925A1 AU2020323925A AU2020323925A AU2020323925A1 AU 2020323925 A1 AU2020323925 A1 AU 2020323925A1 AU 2020323925 A AU2020323925 A AU 2020323925A AU 2020323925 A AU2020323925 A AU 2020323925A AU 2020323925 A1 AU2020323925 A1 AU 2020323925A1
Authority
AU
Australia
Prior art keywords
antibody
fragment
sequences
clone
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020323925A
Other languages
English (en)
Inventor
James E. Robinson
Russell B. Wilson
Hong Xin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stadius Biopharma LLC
Tulane University
Louisiana State University
Original Assignee
Stadius Biopharma LLC
Tulane University
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stadius Biopharma LLC, Tulane University, Louisiana State University filed Critical Stadius Biopharma LLC
Publication of AU2020323925A1 publication Critical patent/AU2020323925A1/en
Assigned to THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE, Stadius Biopharma, LLC reassignment THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND Request for Assignment Assignors: AUTOIMMUNE TECHNOLOGIES, LLC, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020323925A 2019-07-29 2020-07-28 Antibodies to Candida and uses thereof Abandoned AU2020323925A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962879894P 2019-07-29 2019-07-29
US201962879912P 2019-07-29 2019-07-29
US62/879,894 2019-07-29
US62/879,912 2019-07-29
PCT/US2020/043908 WO2021021830A1 (en) 2019-07-29 2020-07-28 Antibodies to candida and uses thereof

Publications (1)

Publication Number Publication Date
AU2020323925A1 true AU2020323925A1 (en) 2022-03-17

Family

ID=74230808

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020323925A Abandoned AU2020323925A1 (en) 2019-07-29 2020-07-28 Antibodies to Candida and uses thereof

Country Status (8)

Country Link
US (1) US20220280618A1 (https=)
EP (1) EP4007772A4 (https=)
JP (1) JP7667773B2 (https=)
KR (1) KR102822827B1 (https=)
CN (1) CN114901688A (https=)
AU (1) AU2020323925A1 (https=)
CA (1) CA3146123A1 (https=)
WO (1) WO2021021830A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115991752B (zh) * 2022-12-07 2025-10-31 中国科学技术大学 特定组氨酸甲基化修饰的pra1蛋白免疫原、多克隆抗体及应用
WO2025090760A1 (en) * 2023-10-25 2025-05-01 Board Of Regents, The University Of Texas System Antibodies specific to scube3 and methods of use
CN119930808B (zh) * 2025-01-09 2025-11-25 普健生物（武汉）科技有限公司 一种抗白念珠菌Csa2蛋白的单克隆抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2651575B2 (ja) * 1987-07-13 1997-09-10 神鋼電機株式会社 インバータの過電流検出装置
WO2000061637A1 (en) * 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
GB0505489D0 (en) * 2005-03-18 2005-04-20 Domantis Ltd Antibodies
EP2102244A2 (en) * 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2699257A4 (en) 2011-04-21 2014-10-15 Univ Louisiana State PEPTIDE AND CONJUGATE VACCINES FOR FUNGI INFECTIONS
US10590178B2 (en) 2014-06-25 2020-03-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Chimeric vaccine against fungal infections
EP3277707A4 (en) * 2015-04-01 2018-08-08 Taipei Medical University Antibodies against infectious diseases
CN108368172B (zh) * 2015-07-15 2022-06-14 根马布股份公司 人源化或嵌合cd3抗体
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same

Also Published As

Publication number Publication date
KR20220113346A (ko) 2022-08-12
JP2022542699A (ja) 2022-10-06
KR102822827B1 (ko) 2025-06-19
US20220280618A1 (en) 2022-09-08
EP4007772A4 (en) 2023-11-29
CA3146123A1 (en) 2021-02-04
EP4007772A1 (en) 2022-06-08
JP7667773B2 (ja) 2025-04-23
CN114901688A (zh) 2022-08-12
WO2021021830A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
US20210277092A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
WO2021195326A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195485A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
JP7667773B2 (ja) カンジダ属に対する抗体およびその使用法
WO2020061159A1 (en) Human antibodies to zika virus
US20230063625A1 (en) Human antibodies to rift valley fever virus
WO2021195385A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
US20240026035A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
US11299535B2 (en) Human IgE antibodies binding to aspergillus allergens
US20230181714A1 (en) Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
US20230085393A1 (en) Human antibodies that neutralize zika virus and methods of use therefor
US20240085427A1 (en) AN AGR2Xcd3 BISPECIFIC ENGAGER FOR THE TREATMENT OF CANCER
US20250145691A1 (en) Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein
WO2023187407A1 (en) Human monoclonal antibodies binding to sars-cov-2 and methods of use thereof
US20240288426A1 (en) Human antibodies to crimean congo hemorrhagic fever virus
WO2024015760A2 (en) Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
WO2023235666A2 (en) Human antibodies to bordetella pertussis and uses therefor
KR20260047586A (ko) 인플루엔자 b 바이러스에 대한 광범위 반응성 항체
CN116529259A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

Free format text: FORMER APPLICANT(S): THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE; THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND; AUTOIMMUNE TECHNOLOGIES, LLC

Owner name: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

Free format text: FORMER APPLICANT(S): THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE; THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND; AUTOIMMUNE TECHNOLOGIES, LLC

Owner name: STADIUS BIOPHARMA, LLC

Free format text: FORMER APPLICANT(S): THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE; THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND; AUTOIMMUNE TECHNOLOGIES, LLC

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period